MYP_117812
Tafasitamab
Anticancer
Immunology
▸
Immune modulation
▸
Immunomodulatory activity
Standard
451 amino acids
C2212H3409N579O681S18
Standard
EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKALPAPEEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
49586.37 Da
7.97
2.63
1.66
0.0058
-0.42
0.61
0.02
43.16
66.87
0.0998
76780.00
77405.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Amino Acid Composition
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
RECORD: Rec_0084693
VERIFIED: NO
Provenance & Taxonomy
Cricetulus griseus [Animal]
Monoclonal antibody
10029
Structure & Mods
cyclic peptide scaffold [Cyclic]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
-
The terminal elimination half-life of tafasitamab is approximately 17 days.[L15292]
RECORD: Rec_0269910
VERIFIED: NO
Provenance & Taxonomy
Cricetulus griseus [Animal]
Monoclonal antibody
10029
Structure & Mods
cyclic peptide scaffold [Cyclic]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Anticancer
The terminal elimination half-life of tafasitamab is approximately 17 days.[L15292]
RECORD: Rec_0415205
VERIFIED: NO
Provenance & Taxonomy
Cricetulus griseus [Animal]
Monoclonal antibody
10029
Structure & Mods
cyclic peptide scaffold [Cyclic]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Immunomodulatory
The terminal elimination half-life of tafasitamab is approximately 17 days.[L15292]